Abilify Gambling Injury Lawsuits Will Move Forward to Preliminary Trials

Abilify Gambling Addiction Injuries

Plaintiffs have successfully defeated Otsuka Pharmaceutical and Bristol-Meyers Squibb’s motion to dismiss multidistrict litigation relating to alleged compulsive behavior side effects of the widely prescribed drug Abilify. As reported by Law360, U.S. District Judge M. Casey Rodgers issued a decision on March 16th finding that “consumers have shown their … evidence is sound and reliable and that there is a genuine dispute of material fact over whether Abilify can cause compulsive behavior.” [Read more…]

Lexi Hazam Named to Plaintiffs Executive Committee in Nationwide Abilify Drug Injury Litigation

Lexi Hazam Named to Plaintiffs Executive Committee in Nationwide Abilify Drug Injury Litigation

On December 16, 2016, Chief Judge M. Casey Rodgers of the U.S. District Court for the Northern District of Florida issued an order appointing Lexi J. Hazam of Lieff Cabraser to the Plaintiffs’ Executive Committee in the multidistrict litigation previously consolidated in October 2016 over injuries and financial losses sustained by patients as a result of their use of the prescription drug Abilify. [Read more…]

Bristol-Myers Squibb Pays $19.5 Million Over Improper Abilify Drug Marketing

Abilify Gambling Addiction Injuries

Bristol-Myers Squibb has agreed to pay $19.5 million to settle claims of improper advertising relating to its top-selling drug Abilify. 42 states and Washington D.C. alleged that the company improperly advertised antipsychotic drug Abilify, first approved in 2002 by the FDA to treat schizophrenic in adults. However, Bristol-Myers Squibb thereafter began promoting Abilify for off-label uses not approved by the FDA. These off-label uses had not been established as safe or effective. [Read more…]

Abilify Gambling Lawsuits Consolidated in Florida Federal Court

Abilify Gambling Lawsuits Consolidated in Florida Federal Court

The Judicial Panel on Multidistrict Litigation has consolidated more than 20 lawsuits against Bristol-Myers Squibb Co. over claims of pathological gambling side effects in patients using the antipsychotic drug Abilify in federal court in Florida. The serious impulse-control problems described in the complaints reportedly stop when the medicine is discontinued. 22 actions pending in 12 districts will be centralized under Chief District Judge M. Casey Rodgers. [Read more…]

Lieff Cabraser Announces Filing of Personal Injury Lawsuit Against Bristol-Myers Squibb and Otsuka Pharmaceutical for Damages Caused by Abilify Prescription Drug

high contrast image of casino roulette

Gambling addiction lawsuit alleges claims including Strict Liability, Negligent Misrepresentation, and Fraudulent Concealment, and seeks damages for neuropsychiatric, mental, physical, and economic damages, as well as punitive damages

Lexi J. Hazam of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announces that Rikki Carlson of Fall River, Massachusetts, has filed a personal injury lawsuit against Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., and Otsuka America Pharmaceutical, Inc. (“Defendants”) for damages suffered as a direct and proximate result of Defendants’ wrongful conduct in connection with the development, design, testing, labeling, packaging, promoting, advertising, marketing, distribution, and selling of the blockbuster prescription drug Abilify.

[Read more…]

FDA Warning: Antipsychotic Drug Abilify Linked to Severe Compulsive Behavior and Addiction

FDA Warning: Antipsychotic Drug Abilify Linked to Severe Compulsive Behavior and Addiction

The Food and Drug Administration (FDA) has issued a formal warning that the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and also used in generic versions of the drug) has been linked to compulsive urges, which can lead to uncontrollable gambling, among other addictions. These rare but serious impulse-control problems reportedly stop when the medicine is discontinued or markedly reduced in dosage. [Read more…]